Form 4: MAIA Biotechnology Head of Finance Acquires Stock Options

Jeffrey Himmelreich, Head of Finance at MAIA Biotechnology, Inc., reports the acquisition of stock options.

Summary

• On April 30, 2024, Jeffrey C Himmelreich, Head of Finance at MAIA Biotechnology, Inc., filed a Form 4.
• The form reports a transaction involving derivative securities, specifically stock options.
• Himmelreich acquired 10,000 stock options with an exercise price of $2.94 on April 26, 2024.
• These options, granted under the company's 2021 Equity Incentive Plan, vest over four years.
• 25% of the options vest on the first anniversary of the grant date, and the remaining options vest ratably monthly over the following 36 months.
• Following the reported transaction, Himmelreich beneficially owns 10,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by an executive suggests confidence in the company, but it's a routine transaction.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotechnology sector.
• Vesting schedules, such as the 4-year vesting with a 1-year cliff described in the document, are typical to incentivize long-term commitment.
• The specific number of options granted and the exercise price would need to be compared to similar companies of MAIA Biotechnology's size and stage to determine if they are in line with industry standards.

Key Dates